Avalo Therapeutics, Inc. (AVTX)

NASDAQ: AVTX · IEX Real-Time Price · USD
5.07
-0.16 (-3.06%)
Aug 17, 2022 4:30 PM EDT - Market closed
-3.06%
Market Cap 47.73M
Revenue (ttm) 3.78M
Net Income (ttm) -71.63M
Shares Out 9.41M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jul 8, 2022
Volume 40,168
Open 5.15
Previous Close 5.23
Day's Range 4.82 - 5.25
52-Week Range 2.42 - 38.88
Beta 1.42
Analysts Buy
Price Target 43.35 (+755.0%)
Earnings Date Aug 1, 2022

About AVTX

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19... [Read more...]

Industry Biotechnology
IPO Date Oct 15, 2015
Employees 42
Stock Exchange NASDAQ
Ticker Symbol AVTX
Full Company Profile

Financial Performance

In 2021, AVTX's revenue was $5.40 million, a decrease of -19.42% compared to the previous year's $6.70 million. Losses were -$84.38 million, 32.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for AVTX stock is "Buy." The 12-month stock price forecast is 43.35, which is an increase of 755.03% from the latest price.

Price Target
$43.35
(755.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Avalo Therapeutics Announces Board Changes

WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capita...

Wall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know

The consensus price target hints at a 230.1% upside potential for Avalo Therapeutics, Inc. (AVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2022.

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyt...

Topline Pivotal trial results expected 1H2023 Topline Pivotal trial results expected 1H2023

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

ROCKVILLE, Md. and CAMBRIDGE, United Kingdom, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive lic...

Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company's common stock, par value $0....

Avalo to Present at the 2022 Jefferies Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present at ...

Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosin...

Topline results expected 4Q2022 Topline results expected 4Q2022

Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virt...

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

WAYNE, Pa. and ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and first quarter 2022 financial results.

Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercialize...

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercialize...

Avalo Therapeutics Announces Leadership Transition

Promotes Dr. Garry Neil to Chief Executive Officer Promotes Chris Sullivan to Chief Financial Officer

Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference

WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer

Announces inducement grant under NASDAQ Listing Rule 5635(c)(4) Announces inducement grant under NASDAQ Listing Rule 5635(c)(4)

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Addi...

WAYNE, Pa. and ROCKVILLE, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Avalo Therapeutics to Host Virtual Investor Day on January 6, 2022

WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Avalo Appoints Two New Independent Directors to Its Board

WAYNE, Pa. and ROCKVILLE, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Do Options Traders Know Something About Avalo (AVTX) Stock We Don't?

Investors need to pay close attention to Avalo (AVTX) stock based on the movements in the options market lately.

Avalo to Present at Two Upcoming Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes...

Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of ...

Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapi...